Lyka Labs inks out-licensing deal with US-based generics firm

The market size of the licensed formulations is about $ 1.4 bn as per IMS March 2017, says Lyka

Premium

Lyka Labs

Rakesh Rao Mumbai

Last Updated : May 30 2017 | 12:52 PM IST

Lyka Labs Ltd, a pharmaceutical company that focuses on super specialty segments of injections and dermatology, has entered into an out-licensing & technology transfer deal with an US-based generics company for a basket of 12 sterile injectable formulations for manufacturing, sales and distribution in the US. Lyka has neither disclosed the name of the partnering company nor the financial details of the deal.

The market size of the licensed formulations is approximately $ 1.4 billion as per IMS March 2017. Lyka will be eligible for a royalty on end sales.

“Going forward, Lyka will continue to explore opportunities to monetise its R&D

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in